Unlocking the full potential of molecular glues to develop precision medicines and transform patient lives

Who We Are and What We Do

TRIANA Biomedicines is a venture-backed biopharmaceutical company leading a transformative approach to discover and develop novel therapeutics to treat diseases. Our technology identifies small molecules that promote the interaction between two proteins which alters the fate or function of the disease target protein. One such application aims to activate the innate protein degradation machinery to destroy the disease target. These innovative “molecular glues” allow us to treat diseases in entirely new ways, by pursuing highly relevant disease targets that have long been considered undruggable or are inadequately addressed.

Our target-first and rational approach to molecular glue discovery empowers us to consider a wide-range of therapeutic applications for our products. Our drug discovery efforts are accelerated with emphasis on known disease-causing protein targets. Our initial focus on targeted protein degradation (TPD) is driven by our desire to discover and develop groundbreaking new cancer medicines.

Our Science

It is estimated that roughly 85% of disease targets are undruggable. Molecular glues are a new validated wave of medicines that render undruggable targets druggable.

Molecular glue degraders were serendipitously identified for their preferential cancer-cell killing properties. Later it was discovered that these drugs induce protein:protein interactions between disease targets and a component of the cell’s ubiquitin-proteasome system (UPS). Specifically, the mechanism involves E3 ligase enzymes, which tag target proteins with ubiquitin molecules to be recognized and degraded by the proteasome. This discovery prompted the search for other compounds that could promote degradation of disease targets by “gluing” them onto components of the cell’s UPS.

TRIANA is harnessing the full potential of molecular glues. Our approach is to start with challenging disease targets and leverage our proprietary protein:protein pairing engine to identify E3 ligases that are potential matches. We then initiate a comprehensive glue discovery campaign covering diverse chemical spaces to identify new molecular glues using a target-first and rational approach.

Learn more

Our Team

Our Values

Our Team is our greatest asset at TRIANA. Each member brings a unique set of experiences, perspectives, and skills to the table, enriching our collective knowledge and creativity. We are united by our passion for excellence and our commitment to making a meaningful impact.

Learn about our Culture

Leadership

Dr. Trojer joined TRIANA Biomedicines in November of 2021 as CEO and Board member after a successful career at Constellation Pharmaceuticals where he served as the company’s CSO. Dr. Trojer co-founded Constellation in 2008 and as member of the company’s executive team he materially contributed to several successful financing rounds and deals, including a $100M crossover round, a $65M IPO and the ultimate acquisition of Constellation in 2021 for $1.7b. Under his leadership, Constellation built a robust discovery platform, established a portfolio of competitive clinical candidates and drove the maturation of the company‘s development efforts, leading to one PhIII and two PhII assets and three additional clinical candidates. Dr. Trojer brings 20+ years of experience in transcription and chromatin regulation and 15+ years of drug discovery and oncology experience to TRIANA. He completed his post-doctoral fellowship at NYU, Medical School in the laboratory of Dr. Danny Reinberg and received his Ph.D. in Biochemistry and Molecular Biology from the Leopold-Franzens University of Innsbruck, Austria.

Dr. Germa joined TRIANA Biomedicines in May of 2025 to lead the clinical development of the company's therapeutic products. She is an accomplished medical oncologist and clinical development leader with approximately 25 years of pharmaceutical industry experience in smaller biotech and large pharmaceutical companies, from first-in-human to registrational clinical studies. She led the initial Kisqali® program and registration, and actively contributed to the development of multiple other small molecules and biologics, of which several received FDA approval. Prior to joining TRIANA, she was the CMO at Ikena Oncology where she led the clinical efforts in developing the company’s pipeline. Dr. Germa also served as the CMO at Transcenta Therapeutics, where she played a pivotal role in shaping and successfully executing on the strategic goals for the company’s oncology and non-oncology portfolio, in China, US and rest of world. In addition, Dr. Germa held senior clinical leadership positions at global pharmaceutical companies such as AstraZeneca, Bristol Myers Squibb, and Novartis. Dr. Germa earned her Medical Doctor degree and board certification in Medical Oncology at the University of Lille, France.

Dr. Palombella joined TRIANA Biomedicines in September of 2023. He brings to TRIANA over 30 years of scientific leadership and experience advancing first-in-class therapeutic programs, as well as a successful track record of building drug discovery and development organizations. Prior to joining TRIANA, he was the Chief Scientific Officer (CSO) at Surface Oncology, where he led the non-clinical research and development organization. Prior to that, Dr. Palombella was EVP and CSO at Infinity Pharmaceuticals, where he was responsible for drug discovery and preclinical development. He held roles of increasing scientific responsibility at Syntonix Pharmaceuticals, Millennium Pharmaceuticals, LeukoSite Inc, and ProScript. Dr. Palombella was involved in the discovery and development of bortezomib and duvelisib, both for cancer therapy. Dr. Palombella holds a PhD in Viral Oncology and Immunology from the New York University Medical Center and completed his postdoctoral studies at Harvard University.

Dr. Bala joined TRIANA Biomedicines in May 2026, bringing more than 30 years of experience in program leadership, program development, market access, product strategy, and business development. His expertise spans the full development continuum, from early to late-stage programs, across both small biotech and large pharmaceutical organizations. He has successfully launched seven oncology products globally. Prior to joining TRIANA, he served as Chief Development Officer at Mersana Therapeutics, where he played a key role in business development efforts that culminated in the company’s acquisition by Day One Biopharmaceuticals. Before that, he was Chief Operating Officer at Constellation Pharmaceuticals, where he led multiple development functions, while also contributing significantly to the business activities that led to the company’s acquisition by MorphoSys. Earlier in his career, Dr. Bala held roles of increasing responsibility at TESARO, Sanofi, GlaxoSmithKline, Centocor, and Research Triangle Institute. He holds a Ph.D. in Management Science from the University of Chicago.

Ms. Sousa joined the TRIANA Biomedicines’ team in November 2021 as a people and culture advisor. She brings to TRIANA decades of people, culture and human resources experience in early stage biotechnology organizations. Prior to joining TRIANA, she was the Chief Human Resources Officer at Constellation Pharmaceuticals, where she led the organization through multiple stages of growth from an early research focus to a publicly traded, pre-commercial business and subsequent successful acquisition. Previously, Ms. Sousa was the Vice President of Human Resources and Operations at EPIX Pharmaceuticals. Ms. Sousa held positions of increasing responsibility at RKS Health Ventures concluding with an acquisition by Partners Healthcare. Ms. Sousa received her BS from the University of Massachusetts.

Ms. Valentine joined the TRIANA Biomedicines team in November 2022 as a legal and strategic advisor. She brings to TRIANA over two decades of biotechnology industry experience as a senior business executive and lawyer. Ms. Valentine is the Founder of KHV Advisory, LLC. Prior to her advisory activity, she was the Chief Legal Officer at Constellation Pharmaceuticals, Inc., where she joined pre-IPO and worked with other members of senior management to build the organization, raise additional capital, advance the programs, and close a successful M&A transaction. Previously, Ms. Valentine served as Chief Legal Officer and General Counsel of Agenus Inc. She also worked in the biotech practice group of Palmer & Dodge law firm, representing private and public companies. Karen received her B.A. in neuroscience from Colgate University and her J.D. from Boston University School of Law.

Dr. Plamondon joined TRIANA Biomedicines in October 2024 to lead the manufacturing and drug development of the company's therapeutic products. He brings to TRIANA over three decades of chemistry, manufacturing and drug development experience in both biotech and large pharmaceutical industry settings, and is a recognized leader in the discovery, development, and commercialization of small molecule therapeutics. Prior to joining TRIANA, he was the Executive Vice President and Head of CMC at LifeMine Therapeutics. Previously, at Constellation Pharmaceuticals, Dr. Plamondon was the Senior Vice President of CMC and led the manufacturing and development of all small molecule therapeutic products for the company from Phase I to NDA preparation activities. Dr. Plamondon held positions of increasing responsibility at Vertex Pharmaceuticals, Karyopharm Therapeutics, Tetraphase Pharmaceuticals, Millennium Pharmaceuticals, and Bio-Mega/Boehringer Ingelheim and he is an inventor on multiple patents. Dr. Plamondon received his PhD from the University of Montreal and completed his postdoctoral research in the laboratory of Professor Stuart Schreiber at Harvard University.

Dr. Seyb joined TRIANA Biomedicines in September of 2021 to build and lead the biology and translational sciences team. Previously, she served as VP of Research at Ohana Biosciences, focused on developing novel treatments to improve reproductive health. Dr Seyb held positions of increasing responsibly at Ra Pharmaceuticals, inclusive of leading the biology function from discovery through Phase 2 clinical development, as well as the company’s collaboration with Merck that yielded an orally bioavailable tricyclic peptide inhibitor of PCSK9 currently in clinical development. Dr. Seyb received her Ph.D. in Pharmacology and Toxicology from the University of Kansas.

Dr. Constan joined TRIANA Biomedicines in March 2025. He has over 25 years of experience in nonclinical safety assessment, drug development strategy, and regulatory submissions. He has led toxicology, DMPK, and clinical pharmacology functions in various therapeutic areas and drug modalities. Most recently, he was an independent consultant and guided early nonclinical programs to IND submission for small biotech companies. Previously, he was responsible for the safety evaluation of small molecule and gene therapy programs and oversaw oncology programs from early discovery through late-stage development at Ikena Oncology, Decibel Therapeutics, Infinity Pharmaceuticals, Pfizer, and Rhône-Poulenc Rorer Pharmaceuticals. Dr. Constan earned his Ph.D. in Environmental Toxicology at Colorado State University and trained as a post-doctoral fellow at the Chemical Industry Institute of Toxicology (CIIT) in Research Triangle Park, NC.

Mr. Marsh joined TRIANA Biomedicines in September 2025 to lead and build the clinical development operations of the company's therapeutic products. He is an accomplished drug development professional bringing to TRIANA over two decades of development operations experience in both biotech and large pharmaceutical industry settings. Prior to joining TRIANA, he was the Vice President of Clinical Development Operations at Mariana Oncology a Novartis Company, Vigil Neurosciences, and Synlogic. Mr. Marsh has proven experience in building out clinical development operations functions from the ground up and leading nimble clinical teams through first in human trials, proof of concept, and beyond. He has contributed to the development of three approved products, most recently ZILBRYSQ®, and brings a patient centric focus to clinical development with an emphasis on representing the patients’ voice from study design concept through trial execution. Mr. Marsh has held positions of increasing responsibility at Ra Pharmaceuticals, Onkaido a Moderna Company, Tetraphase Pharmaceuticals, and Ziopharm Oncology. Mr. Marsh received his BSc in Biomedical Engineering from Boston University.

Ms. Ndiaye joined TRIANA Biomedicines in August 2022 to build and lead a fully integrated finance organization. She brings to TRIANA over 18 years of financial expertise in the life science industry, driving operational and strategic initiatives across global pharmaceutical organizations as well as early to mid stage biotech companies. Prior to joining TRIANA, she worked as a senior consultant with Danforth Advisors, leading and optimizing their FP&A practice. Previously, Ms. Ndiaye was Sr. Director of Finance at Sunovion Pharmaceuticals, where she led the R&D Clinical Finance team through change management, with a focus on developing and optimizing the planning, analysis and reporting for both Sunovion US and global clinical development business units. As the Sr. Director Finance and Operations at IFM Therapeutics, she built the company’s FP&A capability. Ms. Ndiaye held positions of increasing responsibilities at Aileron Therapeutics, Genocea Biosciences and Takeda / Millennium Pharmaceuticals. Ms. Ndiaye received her Masters in Finance from Boston College.

Dr. La joined TRIANA Biomedicines in November 2021. He has more than twenty years of drug discovery experience. Prior to joining the company, he was Head of Medicinal Chemistry and Structural Biology at Fog Pharma, where he was the scientific program lead for the company’s flagship oncology program. Previously, he was at Sage Therapeutics and Amgen Inc. where he held roles of increasing responsibility on program teams that ranged from early discovery to development candidate delivery. He is an inventor on 28 patents. Dr. La holds a Ph.D. in Chemistry from Boston College and a post-doctoral research fellowship from Harvard University.

Dr. Wigle joined TRIANA Biomedicines in March 2022. He has over a decade of drug discovery experience. Prior to joining the company, he was Senior Director of Molecular Discovery at Ribon Therapeutics, where he helped deliver three assets into clinical trials. Previously, he was Associate Director of Biochemistry and Biophysics at Warp Drive Bio, where he oversaw a team of scientists responsible for identifying small molecules that induce ternary complexes. He held roles of increasing responsibility and scientific scope at Epizyme and was a key member of the team that discovered Tazemetostat, an FDA approved EZH2 inhibitor for the treatment of patients with follicular lymphoma and epithelioid sarcoma. Dr. Wigle holds a Ph.D. in Pharmaceutical Sciences from The University of North Carolina at Chapel Hill and completed a post-doctoral research fellowship at the Center for Integrative Chemical Biology & Drug Discovery at The University of North Carolina at Chapel Hill.

Scientific Advisory Board

Robert Abraham, PhD
Chair of the SAB

Robert Copeland, PhD

Brian Jones, PhD

Maria Koehler, MD, PhD

David Tuveson, MD, PhD, FAACR

Adrian Senderowicz, MD

Directors

Jigar Raythatha
Chair of the Board, Independent Board Director

Shelley Chu, MD, PhD
Lightspeed Venture Partners

David Grayzel, MD
Atlas Venture

Andrew Hedin
Bessemer Venture Partners

Josh Resnick, MD
RA Capital Management

Lorence Kim, MD
Ascenta Capital

Patrick Trojer, PhD
President & CEO, TRIANA Biomedicines

Christopher O’Donnell, PhD
Pfizer Ventures

Join Us

TRIANA Biomedicines is building the leading molecular glue discovery platform to fundamentally change the paradigm of small molecule drug discovery and bring significant therapeutic benefits to patients.

With our commitment to pioneering science and the people driving it, TRIANA is expanding its team.

Come change the future of medicine with us!